1. POCT – Innovations Dual Path Platform (DPP®) Technology Dr.Talita Franco – Business Development Consultant www.chembio.com
2. National Institutes of Health –NIH Centers for Disease Control & Prevention-CDC The Foundation for Innovative &Novel Diagnostics- FIND The Infectious Disease Research Institute-IDRI The Pan American Health Organization-PAHO World Health Organization-WHO Fundação Oswaldo Cruz– FIOCRUZ Guidelines + Standards+ Colaboration = Sucess
9. POCT ImprovementDPP Increased analytical and clinical sensitivity Outside the standard lateral flow Less labor intensive than EIA, PCR or WB Potential ideal confirmatory test Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc. Multiplex capability through elimination of aggregation issues (ie HIV/TB, HIV 1/ 2, etc.) Requires minimal sample volume Long shelf life (up to 24 months) Total test time < 20 minutes Ideally suited for POC testing
10.
11.
12. Dual Path Platform (DPP®) Technology ORAL FLUID WHOLE BLOOD IN USE : DOMINICA & ST KITTS AND NEVIS
13. DPP™ HIV 1/2 Test Line Control Line PA PA PA PA PA PA gold gold PA PA Ag1 gold PA PA PA gold PA PA PA PA PA PA Ag2 PA = Protein A gold gold Non HIV antibodies HIV antibodies Protein A gold conjugate PA PA HIV Antigens PA PA PA gold PA PA PA PA PA PA gold Ag3 gold PA gold PA PA PA PA S2 strip S1 strip Antibodies in sample
18. Chembio-Branded Public Health Base Complemented by OEM and License Programs Current OEM/Licensees Anticipated OEM/License Areas FIOCRUZ(BRAZIL) INFECTIOUS DISEASES BIORAD VETERINARY HIV SCREEN HCV AB-AG DUAL DPP INFLUENZA SYPHILIS 17
19. Talita Franco International Business Consultant Chembio Diagnostic Systems Inc Tel/Fax:+1(951)239-3139 E.mail: LatAmSales@chembio.com Skype: tsallesusa Homepage: www.chembio.com